Claire Scudder
Senior Trial Manager
I have been working in trial management since 2005, primarily on later Phase II and Phase III CTIMPs, within an Oncology setting. My current research interests are CTIMPs in paediatric populations. I started working at the DIL in May 2017 as the Senior Trial Manager.
Recent publications
-
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
Journal article
Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Journal article
Urbonas V. et al, (2019), Annals of Oncology, 30, 317 - 324
-
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Journal article
Iveson TJ. et al, (2018), The Lancet Oncology, 19, 562 - 578
-
Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma
Conference paper
Middleton MR. et al, (2017), Clinical Trials
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Journal article
Kerr RS. et al, (2016), The Lancet Oncology, 17, 1543 - 1557